-
公开(公告)号：US20120046645A1
公开(公告)日：2012-02-23
申请号：US13285459
申请日：2011-10-31
申请人： ZELING CAI , WEI-XING SHI , XUEJUN P. LIU , JIEJUN WU
发明人： ZELING CAI , WEI-XING SHI , XUEJUN P. LIU , JIEJUN WU
IPC分类号： A61M37/00 , C12N5/0783
CPC分类号： C07K7/08 , A61K38/00 , A61K39/0011 , A61K2039/5158 , A61K2039/57 , C07K7/06 , C07K14/4748 , C12N5/0638 , C12N2501/2302 , C12N2501/2307 , C12N2501/51 , C12N2501/58 , C12N2501/599 , C12N2502/50 , C12N2502/99
摘要： Multiple myeloma (MM) is a clonal B cell malignancy and remains essentially incurable by conventional anti-tumor therapy. Patients with MM have a median survival of only three years. MM is characterized by proliferation and accumulation of mature plasma cells in the bone marrow (BM) leading to bone destruction, BM failure, anemia, and reduced immune function. The identification of MHC Class I, HLA-A2, associated peptides presented on multiple myeloma cells is an important step in developing immunotherapies for MM. Presented here are methods for creating activated T lymphocytes that are cytotoxic to both peptide loaded T2 target cells and multiple myeloma cell lines.
-
公开(公告)号：US20120045829A1
公开(公告)日：2012-02-23
申请号：US13285491
申请日：2011-10-31
申请人： ZELING CAI , WEI-XING SHI , XUEJUN P. LIU , JIEJUN WU
发明人： ZELING CAI , WEI-XING SHI , XUEJUN P. LIU , JIEJUN WU
IPC分类号： C12N5/07
CPC分类号： C07K7/08 , A61K38/00 , A61K39/0011 , A61K2039/5158 , A61K2039/57 , C07K7/06 , C07K14/4748 , C12N5/0638 , C12N2501/2302 , C12N2501/2307 , C12N2501/51 , C12N2501/58 , C12N2501/599 , C12N2502/50 , C12N2502/99
摘要： Multiple myeloma (MM) is a clonal B cell malignancy and remains essentially incurable by conventional anti-tumor therapy. Patients with MM have a median survival of only three years. MM is characterized by proliferation and accumulation of mature plasma cells in the bone marrow (BM) leading to bone destruction, BM failure, anemia, and reduced immune function. The identification of MHC Class I, HLA-A2, associated peptides presented on multiple myeloma cells is an important step in developing immunotherapies for MM. Presented here are methods for creating activated T lymphocytes that are cytotoxic to both peptide loaded T2 target cells and multiple myeloma cell lines.
-
公开(公告)号：US20120045466A1
公开(公告)日：2012-02-23
申请号：US13285517
申请日：2011-10-31
申请人： ZELING CAI , WEI-XING SHI , XUEJUN P. LIU , JIEJUN WU
发明人： ZELING CAI , WEI-XING SHI , XUEJUN P. LIU , JIEJUN WU
CPC分类号： C07K7/08 , A61K38/00 , A61K39/0011 , A61K2039/5158 , A61K2039/57 , C07K7/06 , C07K14/4748 , C12N5/0638 , C12N2501/2302 , C12N2501/2307 , C12N2501/51 , C12N2501/58 , C12N2501/599 , C12N2502/50 , C12N2502/99
摘要： Multiple myeloma (MM) is a clonal B cell malignancy and remains essentially incurable by conventional anti-tumor therapy. Patients with MM have a median survival of only three years. MM is characterized by proliferation and accumulation of mature plasma cells in the bone marrow (BM) leading to bone destruction, BM failure, anemia, and reduced immune function. The identification of MHC Class I, HLA-A2, associated peptides presented on multiple myeloma cells is an important step in developing immunotherapies for MM. Presented here are methods for creating activated T lymphocytes that are cytotoxic to both peptide loaded T2 target cells and multiple myeloma cell lines.
摘要翻译： 多发性骨髓瘤（MM）是克隆性B细胞恶性肿瘤，并且通过常规抗肿瘤治疗基本上不能治愈。 MM患者的中位生存期仅为3年。 MM的特征在于骨髓（BM）中成熟浆细胞的增殖和积累，导致骨破坏，BM衰竭，贫血和免疫功能降低。 在多发性骨髓瘤细胞上呈现MHC I类HLA-A2，相关肽的鉴定是开发MM免疫疗法的重要一步。 这里提出的是产生对加载肽的T2靶细胞和多发性骨髓瘤细胞系具有细胞毒性的活化的T淋巴细胞的方法。
-
公开(公告)号：US08075895B2
公开(公告)日：2011-12-13
申请号：US12564501
申请日：2009-09-22
申请人： Zeling Cai , Wei-Xing Shi , Xuejun P. Liu , Jiejun Wu
发明人： Zeling Cai , Wei-Xing Shi , Xuejun P. Liu , Jiejun Wu
CPC分类号： C07K7/08 , A61K38/00 , A61K39/0011 , A61K2039/5158 , A61K2039/57 , C07K7/06 , C07K14/4748 , C12N5/0638 , C12N2501/2302 , C12N2501/2307 , C12N2501/51 , C12N2501/58 , C12N2501/599 , C12N2502/50 , C12N2502/99
摘要： Multiple myeloma (MM) is a clonal B cell malignancy and remains essentially incurable by conventional anti-tumor therapy. Patients with MM have a median survival of only three years. MM is characterized by proliferation and accumulation of mature plasma cells in the bone marrow (BM) leading to bone destruction, BM failure, anemia, and reduced immune function. The identification of MHC Class I, HLA-A2, associated peptides presented on multiple myeloma cells is an important step in developing immunotherapies for MM. Presented here are methods for creating activated T lymphocytes that are cytotoxic to both peptide loaded T2 target cells and multiple myeloma cell lines.
摘要翻译： 多发性骨髓瘤（MM）是克隆性B细胞恶性肿瘤，并且通过常规抗肿瘤治疗基本上不能治愈。 MM患者的中位生存期仅为3年。 MM的特征在于骨髓（BM）中成熟浆细胞的增殖和积累，导致骨破坏，BM衰竭，贫血和免疫功能降低。 在多发性骨髓瘤细胞上呈现MHC I类HLA-A2，相关肽的鉴定是开发MM免疫疗法的重要一步。 这里提出的是产生对加载肽的T2靶细胞和多发性骨髓瘤细胞系具有细胞毒性的活化的T淋巴细胞的方法。
-
公开(公告)号：US20110070185A1
公开(公告)日：2011-03-24
申请号：US12564501
申请日：2009-09-22
申请人： Zeling Cai , Wei-Xing Shi , Xuejun P. Liu , Jiejun Wu
发明人： Zeling Cai , Wei-Xing Shi , Xuejun P. Liu , Jiejun Wu
CPC分类号： C07K7/08 , A61K38/00 , A61K39/0011 , A61K2039/5158 , A61K2039/57 , C07K7/06 , C07K14/4748 , C12N5/0638 , C12N2501/2302 , C12N2501/2307 , C12N2501/51 , C12N2501/58 , C12N2501/599 , C12N2502/50 , C12N2502/99
摘要： Multiple myeloma (MM) is a clonal B cell malignancy and remains essentially incurable by conventional anti-tumor therapy. Patients with MM have a median survival of only three years. MM is characterized by proliferation and accumulation of mature plasma cells in the bone marrow (BM) leading to bone destruction, BM failure, anemia, and reduced immune function. The identification of MHC Class I, HLA-A2, associated peptides presented on multiple myeloma cells is an important step in developing immunotherapies for MM. Presented here are methods for creating activated T lymphocytes that are cytotoxic to both peptide loaded T2 target cells and multiple myeloma cell lines.
摘要翻译： 多发性骨髓瘤（MM）是克隆性B细胞恶性肿瘤，并且通过常规抗肿瘤治疗基本上不能治愈。 MM患者的中位生存期仅为3年。 MM的特征在于骨髓（BM）中成熟浆细胞的增殖和积累，导致骨破坏，BM衰竭，贫血和免疫功能降低。 在多发性骨髓瘤细胞上呈现MHC I类HLA-A2，相关肽的鉴定是开发MM免疫疗法的重要一步。 这里提出的是产生对加载肽的T2靶细胞和多发性骨髓瘤细胞系具有细胞毒性的活化的T淋巴细胞的方法。
-
公开(公告)号：US08323655B2
公开(公告)日：2012-12-04
申请号：US13285517
申请日：2011-10-31
申请人： Zeling Cai , Wei-Xing Shi , Xuejun P. Liu , Jiejun Wu
发明人： Zeling Cai , Wei-Xing Shi , Xuejun P. Liu , Jiejun Wu
CPC分类号： C07K7/08 , A61K38/00 , A61K39/0011 , A61K2039/5158 , A61K2039/57 , C07K7/06 , C07K14/4748 , C12N5/0638 , C12N2501/2302 , C12N2501/2307 , C12N2501/51 , C12N2501/58 , C12N2501/599 , C12N2502/50 , C12N2502/99
摘要： Multiple myeloma (MM) is a clonal B cell malignancy and remains essentially incurable by conventional anti-tumor therapy. Patients with MM have a median survival of only three years. MM is characterized by proliferation and accumulation of mature plasma cells in the bone marrow (BM) leading to bone destruction, BM failure, anemia, and reduced immune function. The identification of MHC Class I, HLA-A2, associated peptides presented on multiple myeloma cells is an important step in developing immunotherapies for MM. Presented here are methods for creating activated T lymphocytes that are cytotoxic to both peptide loaded T2 target cells and multiple myeloma cell lines.
-
公开(公告)号：US08232101B2
公开(公告)日：2012-07-31
申请号：US13285459
申请日：2011-10-31
申请人： Zeling Cai , Wei-Xing Shi , Xuejun P. Liu , Jiejun Wu
发明人： Zeling Cai , Wei-Xing Shi , Xuejun P. Liu , Jiejun Wu
CPC分类号： C07K7/08 , A61K38/00 , A61K39/0011 , A61K2039/5158 , A61K2039/57 , C07K7/06 , C07K14/4748 , C12N5/0638 , C12N2501/2302 , C12N2501/2307 , C12N2501/51 , C12N2501/58 , C12N2501/599 , C12N2502/50 , C12N2502/99
摘要： Multiple myeloma (MM) is a clonal B cell malignancy and remains essentially incurable by conventional anti-tumor therapy. Patients with MM have a median survival of only three years. MM is characterized by proliferation and accumulation of mature plasma cells in the bone marrow (BM) leading to bone destruction, BM failure, anemia, and reduced immune function. The identification of MHC Class I, HLA-A2, associated peptides presented on multiple myeloma cells is an important step in developing immunotherapies for MM. Presented here are methods for creating activated T lymphocytes that are cytotoxic to both peptide loaded T2 target cells and multiple myeloma cell lines.
摘要翻译： 多发性骨髓瘤（MM）是克隆性B细胞恶性肿瘤，并且通过常规抗肿瘤治疗基本上不能治愈。 MM患者的中位生存期仅为3年。 MM的特征在于骨髓（BM）中成熟浆细胞的增殖和积累，导致骨破坏，BM衰竭，贫血和免疫功能降低。 在多发性骨髓瘤细胞上呈现MHC I类HLA-A2，相关肽的鉴定是开发MM免疫疗法的重要一步。 这里提出的是产生对加载肽的T2靶细胞和多发性骨髓瘤细胞系具有细胞毒性的活化的T淋巴细胞的方法。
-
公开(公告)号：US08323965B2
公开(公告)日：2012-12-04
申请号：US13285491
申请日：2011-10-31
申请人： Zeling Cai , Wei-Xing Shi , Xuejun P. Liu , Jiejun Wu
发明人： Zeling Cai , Wei-Xing Shi , Xuejun P. Liu , Jiejun Wu
CPC分类号： C07K7/08 , A61K38/00 , A61K39/0011 , A61K2039/5158 , A61K2039/57 , C07K7/06 , C07K14/4748 , C12N5/0638 , C12N2501/2302 , C12N2501/2307 , C12N2501/51 , C12N2501/58 , C12N2501/599 , C12N2502/50 , C12N2502/99
摘要： Multiple myeloma (MM) is a clonal B cell malignancy and remains essentially incurable by conventional anti-tumor therapy. Patients with MM have a median survival of only three years. MM is characterized by proliferation and accumulation of mature plasma cells in the bone marrow (BM) leading to bone destruction, BM failure, anemia, and reduced immune function. The identification of MHC Class I, HLA-A2, associated peptides presented on multiple myeloma cells is an important step in developing immunotherapies for MM. Presented here are methods for creating activated T lymphocytes that are cytotoxic to both peptide loaded T2 target cells and multiple myeloma cell lines.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.017 秒)
